All In Biotech

Drug Trial Radar · NCT05288205

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

A Phase 1/2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JAB-21822 in Combination With JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Apr 14, 2022

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Allist Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label phase 1/2a study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of JAB-21822 in combination with JAB-3312 in patients with advanced solid tumors harboring KRAS p.G12C mutation and to determine the RP2D for the combination therapy. In the dose expansion phase, preliminary efficacy and safety of the combination therapy at the RP2D will be further explored in patients with specific cancer harboring KRAS p.G12C mutation.

Conditions

  • KRAS P.G12C
  • Non-small Cell Lung Cancer
  • Colorectal Cancer
  • Pancreatic Ductal Carcinoma

Interventions

  • JAB-21822Drug

    KRAS G12C inhibitor

  • JAB-3312Drug

    SHP2 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. recommended phase-2 dose (RP2D).Time frame: Approximately 2 years
  2. Number of participants with dose limiting toxicitiesTime frame: Approximately 2 years

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of USTC Anhui Provincial Hospital

    Hefei, Anhui, China · Not yet recruiting

  • Pecking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Cancer Hospital Chinese Academy Of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Tiantan Hospital, Captal Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Chest Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Fujian cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • The First Affiliated Hospital Xiamen University

    Xiamen, Fujian, China · Not yet recruiting

  • The first Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Zhujiang Hospital of Southem Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Cancer Hospital Chinese Academy Of medical Sciences Shenzhen Center

    Shenzhen, Guangdong, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital-Mammary gland of internal

    Harbin, Heilongjiang, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • The First Affiliated Hosipital Of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Tongji Hospital Tongji Medical College of Hust

    Wuhan, Hubei, China · Not yet recruiting

  • Renmin Hospital Of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

  • Xiangya Hospital Central South Univesity

    Changsha, Hunan, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • The First Hospital Of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • The Affilated Hospital of Inner Mongolia Medical University

    Hohhot, Neimenggu, China · Not yet recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Not yet recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Not yet recruiting

  • LinYi Cancer Hospital

    Linyi, Shandong, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • The Second Affiliated Hospital Zhejiang School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.